T-cell responses at baseline and during therapy with peginterferon-α and ribavirin are not associated with outcome in chronic hepatitis C infected patients

No correlation was found between the magnitude of pre-treatment HCV-specific T-cell responses and the outcome of pegIFN-α/ribavirin therapy in terms of SVR and RVR. Moreover, the magnitude of HCV-specific T-cell responses declined in all patients early during treatment.